All treatments
Treatment
Ventana DLL3 RxDx assay clinical trials
2 indexed studies · 2 currently recruiting
- RecruitingPHASE3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study for advanced neuroendocrine cancer compares a new drug called obrixtamig with standard chemotherapy. It aims to see if adding obrixtamig helps people live longer and also tests a new device to measure a cancer marker.
For: Extrapulmonary Neuroendocrine Cancer (epNEC)United States · Argentina · Australia - RecruitingPHASE2
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is for adults with certain advanced cancers, including small cell lung cancer. It tests a new treatment called BI 764532 to see if different doses are safe and can shrink tumours. Sometimes, this treatment is called obrixtamig.
For: Small Cell Lung Carcinoma · Neuroendocrine Neoplasms · Extra-pulmonary Neuroendocrine CarcinomaUnited States · Belgium · Bulgaria